Condition
Adverse Event Following Immunisation
Total Trials
5
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
80%
4 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 4 (4)
Trial Status
Completed4
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07158814Phase 4Recruiting
Safety of RSV Preventive Monoclonal Antibody
NCT05794113Not ApplicableCompleted
Comparing the Use of a Mobile App for Surveillance of Adverse Events Following Influenza Immunization to a Web-Based Platform
NCT03969641Phase 4Completed
Safety of RIV4 Versus IIV4 in Pregnant Women
NCT02521974Phase 4CompletedPrimary
A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children
NCT03160820Phase 4Completed
Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine
Showing all 5 trials